KCM
HRTX icon

Kingdon Capital Management’s Heron Therapeutics HRTX Stock Holding History

Kingdon Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-250,000
Closed -$6.9M – 120
2018
Q1 		$6.9M Buy
+250,000
New +$5.67M 0.55% 59

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kingdon Capital Management's HRTX Position: Q4 2019 in Review

Kingdon Capital Management sold out of Heron Therapeutics (HRTX) in Q4 2019, closing a stake of 505,729 shares — an estimated $9.36M sold.

Kingdon Capital Management first reported a position in HRTX in Q1 2014 and held it in 23 quarters. The position peaked at $46.5M in Q3 2016. 199 funds tracked by Wall St. Rank hold HRTX as of Q4 2019.

  • Kingdon Capital Management reported no remaining Heron Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Kingdon Capital Management sold 505,729 Heron Therapeutics shares in Q4 2019, an estimated $9.36M.
  • Kingdon Capital Management first reported a position in Heron Therapeutics in Q1 2014 and held it in 23 quarters.
  • Kingdon Capital Management's Heron Therapeutics position peaked at $46.5M in Q3 2016.
  • 199 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2019.

Based on Kingdon Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.